Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma 32Lymphoma, Follicular 26Myelodysplastic Syndromes 24Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Non-Hodgkin 23Leukemia, Myeloid, Chronic-Phase 23Burkitt Lymphoma 22Leukemia, Myeloid, Accelerated Phase 21Leukemia, Myeloid, Acute 20Lymphoma, Large-Cell, Immunoblastic 19Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Mantle-Cell 16Lymphoma, B-Cell, Marginal Zone 16Graft vs Host Disease 16Multiple Myeloma 15Dendritic Cell Sarcoma, Interdigitating 15Blast Crisis 15Myeloproliferative Disorders 14Leukemia, Myelomonocytic, Chronic 14Hodgkin Disease 14Anemia, Refractory, with Excess of Blasts 13Recurrence 11Neoplasms, Plasma Cell 11Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 11Congenital Abnormalities 11Myelodysplastic-Myeloproliferative Diseases 10Leukemia, Biphenotypic, Acute 10Sezary Syndrome 8

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × Methylprednisolone × Clear all
NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Ipsen

Phase 1/2 Completed
400 enrolled 22 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡